FineMark National Bank & Trust decreased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 104,609 shares of the company's stock after selling 3,639 shares during the quarter. FineMark National Bank & Trust's holdings in Johnson & Johnson were worth $15,129,000 as of its most recent filing with the SEC.
Other hedge funds have also recently added to or reduced their stakes in the company. MRP Capital Investments LLC increased its position in Johnson & Johnson by 4.1% in the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock worth $237,000 after buying an additional 65 shares during the last quarter. Werba Rubin Papier Wealth Management grew its stake in shares of Johnson & Johnson by 3.3% during the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company's stock worth $301,000 after acquiring an additional 66 shares during the period. Denali Advisors LLC increased its holdings in Johnson & Johnson by 1.3% in the 4th quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock worth $742,000 after acquiring an additional 67 shares during the last quarter. Sage Mountain Advisors LLC raised its stake in Johnson & Johnson by 0.5% in the 4th quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock valued at $2,106,000 after acquiring an additional 67 shares during the period. Finally, Corepath Wealth Partners LLC lifted its holdings in Johnson & Johnson by 3.7% during the fourth quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company's stock valued at $287,000 after purchasing an additional 70 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.
Johnson & Johnson Trading Down 1.3 %
NYSE:JNJ traded down $2.15 during trading hours on Tuesday, reaching $161.14. The company's stock had a trading volume of 7,455,754 shares, compared to its average volume of 7,086,516. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a market capitalization of $388.32 billion, a price-to-earnings ratio of 24.23, a PEG ratio of 2.56 and a beta of 0.47. The firm has a 50-day simple moving average of $157.70 and a 200-day simple moving average of $156.14. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. During the same period in the previous year, the firm earned $2.29 EPS. The business's quarterly revenue was up 5.3% on a year-over-year basis. Research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.08%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson's payout ratio is currently 74.59%.
Analysts Set New Price Targets
A number of brokerages recently commented on JNJ. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Bank of America increased their target price on Johnson & Johnson from $159.00 to $171.00 and gave the stock a "neutral" rating in a research report on Wednesday, March 5th. Morgan Stanley reduced their price target on Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Raymond James dropped their price objective on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a report on Thursday, January 23rd. Finally, Stifel Nicolaus decreased their price target on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $171.33.
Check Out Our Latest Analysis on Johnson & Johnson
Insiders Place Their Bets
In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
